首页> 外文期刊>Assay and drug development technologies >Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
【24h】

Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.

机译:开发和实施 384 孔均相荧光强度高通量筛选测定法,以鉴定丝裂原活化蛋白激酶磷酸酶-1 双特异性蛋白磷酸酶抑制剂。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We report here the miniaturization, development, and implementation of a homogeneous 384-well fluorescence intensity high-throughput screening (HTS) assay for identifying mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) dual-specificity phosphatase inhibitors. As part of the National Institutes of Health (NIH) Molecular Libraries Screening Center Network (MLSCN), the MKP-1 assay was utilized to screen an NIH diversity library of 65,239 compounds for inhibitors of MKP-1 activity at 10 microM and was also used to confirm the concentration dependence of active agents identified in the primary screen. We observed 100 (0.15) compounds that inhibited MKP-1 in vitro by > or =50 at 10 microM in the primary assay, and 46 of the 100 compounds were confirmed as concentration-dependent inhibitors of MKP-1 with 50 inhibitory concentration (IC(50)) values of <50 microM; four exhibited IC(50) values <1.0 microM, six produced IC(50) values in the 1-10 microM range, and 36 produced IC(50) values in the 10-50 microM range. A clustering and classification analysis of the compound structures of the 46 confirmed MKP-1 inhibitors produced 29 singleton structures and seven clusters of related structures. Some MKP-1 inhibitors were members of structural classes or contained substructure pharmacophores that previously were reported to inhibit either MKP-1 or other protein tyrosine phosphatases, validating the HTS assay. Importantly, we have identified several attractive and novel MKP-1 inhibitor structures that warrant further investigation as potential probes to study the biology of MKP-1 and its role in controlling the amplitude and/or duration of MAPK signaling, cell survival, and tumor progression.
机译:我们在这里报告了用于鉴定丝裂原活化蛋白激酶 (MAPK) 磷酸酶-1 (MKP-1) 双特异性磷酸酶抑制剂的均相 384 孔荧光强度高通量筛选 (HTS) 测定的小型化、开发和实施。作为美国国立卫生研究院 (NIH) 分子库筛选中心网络 (MLSCN) 的一部分,MKP-1 测定用于筛选 NIH 多样性库,该文库包含 65,239 种化合物,用于筛选 10 μM 的 MKP-1 活性抑制剂,还用于确认在初筛中鉴定的活性药物的浓度依赖性。在一级测定中,我们观察到 100 种 (0.15%) 化合物在体外抑制 MKP-1 的 > 或 =50%,100 种化合物中有 46 种被确认为 MKP-1 的浓度依赖性抑制剂,50% 抑制浓度 (IC(50)) 值为 <50 μM;4 个表现出 IC(50) 值 <1.0 μM,6 个产生 1-10 μM 范围内的 IC(50) 值,36 个产生 10-50 μM 范围内的 IC(50) 值。对 46 种已确认的 MKP-1 抑制剂的化合物结构进行聚类和分类分析,产生了 29 个单体结构和 7 个相关结构簇。一些 MKP-1 抑制剂是结构类的成员或含有亚结构药效团,这些药效团以前被报道可抑制 MKP-1 或其他蛋白酪氨酸磷酸酶,验证了 HTS 测定。重要的是,我们已经确定了几种有吸引力且新颖的 MKP-1 抑制剂结构,值得进一步研究作为潜在的探针,以研究 MKP-1 的生物学及其在控制 MAPK 信号转导的幅度和/或持续时间、细胞存活和肿瘤进展中的作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号